SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Immunomedics (IMMU) - moderated
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: urslor who wrote (56151)5/4/2020 10:37:29 AM
From: KeeptheFaith4 Recommendations

Recommended By
idahoranch1
jargonweary
jhcimmu
summer_sky

   of 63280
 
I am unsure of accounting rules for revenue recognition for the sale of Trodelvy. I doubt it is cash basis, but rather accrued after estimating rebates. The question is when is the revenue accrued? At point of sale, day of shipment, day of billing regardless of when product is used in patient, etc.? At any rate, I do not think IMMU is waiting for a check to clear from an insurance company prior to recording revenue.

- KTF

pwc.fr
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News